Health care providers should not use non-invasive prenatal screening tests alone to diagnose genetic abnormalities due to the potential for false results, the Food and Drug Administration warned last week. Also known as cell-free DNA tests or non-invasive prenatal tests, these laboratory developed tests in most cases are not reviewed by the FDA.

“Patients and health care providers should be aware of the risks and limitations of using these genetic prenatal screening tests and that they should not be used alone to diagnose chromosomal (genetic) abnormalities,” FDA said, citing reports that some patients and providers have made critical health care decisions based on the results without additional confirmatory testing. 

Related News Articles

Perspective
When a man sped his pickup truck down a New Orleans street on New Year’s Day killing 14 people and injuring more than 30, area hospitals and health…
Headline
In this conversation, three experts from Boston Medical Center discuss the development of its Health Equity Accelerator, the partnerships needed to sustain the…
Headline
The Food and Drug Administration Dec. 31 released an alert highlighting a Baxter letter that recommended health care providers not use certain lots of Solution…
Headline
The Centers for Disease Control and Prevention Dec. 18 announced that a patient in Louisiana was hospitalized with a severe case of H5N1 bird flu, the first…
Headline
In this conversation, Terry Scoggin, CEO of Titus Regional Medical Center, discusses how the organization designed a system of care to ensure that every…
Headline
In this AHA blog Aisha Syeda, senior program manager for AHA’s Strategic Initiatives, summarizes five action steps hospitals can take to establish pediatric…